Lewis Lab Awarded the 2017 CTSC Highly Innovative Grant

Jamal Lewis

The Clinical and Translational Science Center has awarded the Immunomodulatory Biomaterials Lab (IMBL) with this year’s Highly Innovative grant to develop a microbe-mimicking particulate therapeutic for shellfish allergy.  The overall objective of this CTSC pilot grant is to evaluate efficacy of a Polysaccharide-based microparticle system encapsulating hypoallergens to mitigate allergen-specific reactions in hypersensitized mice following oral administration. This project incorporates both novel immunomodulatory biomaterials and engineered allergens to generate a system that is efficacious, safe and clinically translatable. Through collaborative efforts between the biomedical engineering department (Lewis Lab), and the school of medicine (Patrick Leung – Rheumatology/ Clinical Immunology, Andreas Baumler – Microbiology), the results of this proposal, if successful, are expected to have a positive translational impact on therapy of shellfish allergy.